Roundtable Discussion: Navigating Access & Reimbursement Challenges in Europe
- Discuss the major differences in reimbursement pathways between the US and European markets
- Examine how pricing, evidence generation, and value demonstration impact payer negotiations and long-term sustainability of cell therapies
- Discuss practical steps developers can take early in clinical and regulatory planning to prepare for country-specific reimbursement challenges and accelerate access post-approval